Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Idiopathic Membranous Nephropathy
ChiCTR2200055179Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in idiopathic membranous glomerulonephritis (IMG), sponsored by Qilu Hospital of Shandong University. Primary endpoint: 24-hour urine protein. Started Jan 2022; status: recruiting.
02
Drugs
telitacicept
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2200055179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055179.